PL9643, a melanocortin receptor pan-agonist, improved subjective and objective outcomes within 2 weeks of treatment in patients with moderate or severe dry eye disease, according to a study.
In his presentation at the virtual Association for Research in Vision and Ophthalmology meeting, Kenneth Kenyon, MD, said that current therapies inadequately address the multifactorial inflammation and aqueous deficiency that affect patients with dry eye disease.
“The melanocortins are a new and particularly exciting group of compounds that are notable for their anti-inflammatory properties,” he